Reasons to Include Alcon (ALC) in Your Portfolio Right Now [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
Strong financial stability in times of economic turmoil bodes well for the stock. However, concerns remain about the macroeconomic headwinds, which may strain the company's margin performance. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #2 (Buy) stock has advanced 14.6% compared with the 12.1% rise of the industry and the 28% growth of the S&P 500 composite. The renowned pharmaceutical and medical device manufacturer has a market capitalization of $44.75 billion. ALC's earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 5.3%. Let's delve deeper. Upsides New Products Drive Growth: Alcon dominates the Presbyopia-correcting Intraocular Lens (PCIOLs) market with more than 80% share in the United States alone and more than 60% globally. In Surgical, products like PanOptix and Vivity are solidifying the company's market-leading position in PCIOLs despite the entry of new pla
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers defended at BofA as Lilly fights compounded GLP-1s [Seeking Alpha]Seeking Alpha
- Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health, Inc. (NYSE: HIMS) had its price target raised by analysts at Bank of America Co. from $22.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Hims & Hers Health, Inc. (NYSE: HIMS) had its price target raised by analysts at Bank of America Co. from $17.25 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Hims & Hers Health Stock Soared This Week: Here's Why [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 5/6/24 - Beat
HIMS
Sec Filings
- 6/20/24 - Form 144
- 6/18/24 - Form 4
- 6/18/24 - Form 4
- HIMS's page on the SEC website